Proteomics
Explore targeted and discovery proteomics panels designed to reveal precise protein-level insights. By integrating proteomics with metabolomics, you can drive more powerful scientific discoveries and seamlessly combine data across studies.
Redefining population health research
Proteomics is transforming population health research, offering molecular insights that deepen our understanding of health, disease development, and the biological links that connect diverse conditions.
Each proteomic panel in the Nightingale Health portfolio provides unique strengths. Our experts are here to guide you in selecting the right panels to match your research goals.
When combined with metabolomics, proteomics delivers even greater value – enhancing analytical robustness and opening new scientific opportunities.
Alamar NULISA™ proteomics panels
Unprecedented biomarker quantitation with ultra sensitive detection.
Unlocking the power of precision proteomics
Alamar’s advanced NULISA™ proteomics panels deliver exceptional accuracy and sensitivity, enabling reliable measurement of the most clinically and biologically relevant proteins in blood.
These panels are specifically designed to capture ultra low–abundance biomarkers related to brain health and inflammatory response, providing comprehensive views of systemic and neurodegenerative disease processes.
Alamar NULISAseq™ Neuro 220 Panel
- Sensitivity meets specificity – 220 key neurodegeneration biomarkers measured with high sensitivity and specificity
- Complete Alzheimer’s coverage, expanding on CNS core biomarkers
- Broadest Tau isoform coverage, including 12 assays covering brain-derived and peripheral measures
- Deep profiling for Parkinson’s disease
- Strong coverage of upstream markers for brain health conditions, including for non-AD dementia, ALS, multiple sclerosis, gliomas, and brain injury
- Reveals molecular links across vascular and brain health
- Ultra-high sensitivity enables high detection rates in blood from pre-symptomatic individuals
Alamar NULISAseq™ Inflammation Panel 250
- Profiling of inflammatory response with unmatched sensitivity
- Powerful to study aging and any disease with an inflammatory component
- Comprehensive coverage of both innate and adaptive immunity
- Captures numerous specific immune signaling molecules that are not detected by any other assay, making it ideal for studies on drug effects
- Absolute quantification panel for 150 of the same proteins also available
Alamar NULISAseq™ Immune 340 Panel
- Extensive immune coverage with 340 proteins spanning key immune and regulatory networks
- Diverse disease applicability, enabling insights across cancer immunology, autoimmune disease, inflammation, infectious disease, and aging
- Deep immune profiling of innate and adaptive pathways, including cytokines, chemokines, immune checkpoints, complement, and cell-death signalling
- Attomolar sensitivity for detecting low-abundance immune signals often missed by conventional assays, revealing new insights into disease biology, patient heterogeneity, and treatment response
Olink™ proteomics panels
Broadest biological coverage in a single assay.
Powerful, NGS-based proteomics – effortlessly uncover meaningful insights
Olink™ Reveal and Olink™ Explore HT panels offer extensive, high resolution proteomic profiling designed to capture proteins relevant to virtually any disease area.
With unmatched coverage across key biological pathways, these panels enable researchers to uncover connections between diseases at the molecular level and accelerate new biomarker discoveries.
Olink™ Reveal
- Powerful content curated to provide actionable insights
- Covers over 10% of all plasma proteins
- Excellent coverage of immune response, including 100+ cytokine and chemokines ligands and receptors
- Balanced coverage of other pathways, with >60% of all Reactome pathways covered
- Proteins on the panel are included due to proven disease relevance and robust measurement
Olink™ Explore HT
- Capture the broadest biological insights with proven specificity
- One of the most comprehensive proteomics assays: covering around 50% of canonical plasma proteins
- Ideal for broad discovery science where every protein matters such as clinical trials and gene-to-protein studies
- Chosen for profiling the entire UK Biobank by the UKB Pharma Proteomics Project
Watch Nightingale Health’s latest webinars on proteomics
Fill out the form below to watch our latest proteomics webinar recordings and discover how our technology can support your research. Learn more about our platform and the proteomics panels available in our product offering.